Navigation Links
OncoSec Medical to Attend 6th Annual Fire, Ice and Beyond: The Future of Ablation Therapies Conference
Date:9/22/2011

SAN DIEGO, Sept. 22, 2011 /PRNewswire/ -- OncoSec Medical Incorporated (OTCBB: ONCS), which is developing its advanced-stage OMS ElectroOncology therapies to treat solid tumor cancers, announced today that the company will be hosting an exhibition table at the 6th Fire, Ice and Beyond: The Future of Ablation Therapies conference in Las Vegas, NV, September 23-24. OncoSec's exhibition will highlight a poster presentation providing preliminary results from their phase IV head and neck cancer and phase I breast cancer trials carried out in Europe using OncoSec's OMS ElectroChemotherapy™ treatment approach.

(Logo: http://photos.prnewswire.com/prnh/20110314/MM64943LOGO)

"We are pleased to highlight at this important scientific conference the extent of our clinical development activities of our OMS ElectroChemotherapy™ program and begin to share validating data from prior clinical trials that supports the merits of the therapy," said Punit Dhillon, president and CEO of OncoSec. "Our aim is to complete data analysis from the previous OMS ElectroChemotherapy™ programs and present this clinical data at applicable oncology and scientific meetings and seek a commercialization path for the product with the help of one or more industry partnerships from select geographic regions or globally."

Through its asset acquisition, OncoSec has accumulated a significant database of clinical data in a variety of tumor types using the OMS ElectroChemotherapy™ therapeutic approach.  To date OMS ElectroChemotherapy™ has been tested in several clinical trials ranging from Phase I through Phase IV conducted in 13 countries across over 50 sites.  Human data has been collected in over 400 patients with cancers ranging from basal and squamous cell carcinomas, melanoma, adenocarcinoma, Kaposi's sarcoma, pancreatic, hepatic, oral, and head and neck cancers. 

The 6th Fire, Ice, and Beyond: The Future of Ablation Therapies is an advanced program presenting guidance in understanding the expanding field of new and cutting edge energy sources, combination therapies, embolic pharmaceuticals, treatment planning, fusion imaging, and navigation that make up Interventional Oncology procedures. This conference will be attended by physicians, scientists, and business executives in their areas of expertise.

About OncoSec Medical Inc.

OncoSec Medical Incorporated (OTCBB: ONCS) develops novel OMS ElectroOncology therapies that combine its proprietary electroporation delivery technology with a chemotherapeutic or novel DNA-based immunotherapeutics. Targeted local delivery of these agents is designed to achieve selective destruction of cancerous tumors while sparing healthy normal tissue, resulting in improved functional, cosmetic and quality of life outcomes. These therapies have achieved validating safety and efficacy data in early and late stage clinical studies of over 400 cancer patients. OncoSec's clinical programs include three Phase II clinical trials. More information is available at www.oncosec.com.

This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward looking statements." Forward looking statements are based on management's current preliminary expectations and are subject to risks and uncertainties which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition and market conditions. These and additional risks and uncertainties are more fully described in OncoSec's filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward looking statements which speak only as of the date they are made. OncoSec disclaims any obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.


'/>"/>
SOURCE OncoSec Medical Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. OncoSec Medical Licenses Non-DNA Vaccine Tumor Therapy Technology from Inovio Pharmaceuticals
2. Inovio Pharmaceuticals Licenses Non-DNA Vaccine Tumor Therapy Technology to OncoSec Medical
3. OncoSec Medical to Present at ROTH 23rd Annual Growth Stock Conference
4. OncoSec Medical Closes $1.1M Financing
5. OncoSec Medical Closes Purchase and License Agreement for Tumor Therapy Technology with Inovio Pharmaceuticals
6. OncoSec Medical Announces the Appointment of Dr. Anthony E. Maida, III, to Its Board of Directors
7. OncoSec Medical Appoints Engineering Leader
8. OncoSec Medical to Present at Industry and Investor Conferences
9. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
10. You May Have a Thyroid Problem and Not Know It - Particularly If Youre Over 60, Says a New Harvard Medical School Report
11. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/6/2017)... N.Y. , Sept. 6, 2017   PDI , ... announced it will host an educational session focused on ... bloodstream infection (CLABSI) prevention at the 2017 Annual Scientific ... which will take place at the Phoenix ... from Sept. 16-19, will also feature PDI,s ...
(Date:9/5/2017)... Sept. 5, 2017  Xyntek Inc. has announced another milestone in their continued ... office to meet the growing demands of customer engagements regionally.  ... Xyntek's new Midwest office is located at 318 West Adams Street, ... ... regionally. ...
(Date:9/1/2017)... Michael Penna , President and CEO ... for growth in his response to the July 13, ... seeking a buyer for eMDs. Penna,s company, Complete HealthCare ... Value Added Reseller and national leader in the independent ... "As the healthcare market continues to dictate consolidation, healthcare ...
Breaking Medicine Technology:
(Date:9/20/2017)... ... September 20, 2017 , ... “Finn Mouseson”: follows the exciting story of a ... This mouse sets out on a journey that will show that friends are to ... of newly published author and illustrator, Melody Gersonde-Mickelson, who has earned a bachelor’s degree ...
(Date:9/20/2017)... ... September 20, 2017 , ... “Psalms of Humidity”: is ... of mind and move the readers one step closer to God. “Psalms of Humidity” ... that his mistakes that have been made within his life are the very same ...
(Date:9/20/2017)... ... September 20, 2017 , ... “They Sang At Her Funeral”: a tale ... starts revealing the skeletons in their closets. “They Sang At Her Funeral” is the ... years young and married with five children and twelve grandchildren. Before becoming a writer, ...
(Date:9/19/2017)... ... ... Only a few physicians were selected to receive the prestigious 2016 Patients' Choice ... . The founder and medical director of Clevens Face and Body Specialists , ... and the University of Michigan. He has served patients throughout Central Florida and beyond ...
(Date:9/19/2017)... ... 2017 , ... Trusted debt-reduction firm CreditAssociates, LLC has announced two important milestones. ... of $835 million in resolved debt for its clients. , Credit card debt, unpaid ... categories of debt settled by the company. With more than a decade of combined ...
Breaking Medicine News(10 mins):